Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus
Science · 2024
DOI: 10.1126/science.adk6176 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science, 2024. Verfasst von Robert W Cross und 21 weiteren Autor:innen. Beteiligte Einrichtung: Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA. Hauptthemen laut MEDLINE: Ebolavirus, Hemorrhagic Fever, Ebola, Nucleosides, Alanine. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 57 Literaturangaben. Gefördert von: NIAID NIH HHS.
Abstract (Originalsprache)
Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we show that ODV and its circulating parent nucleoside metabolite, GS-441524, have similar in vitro antiviral activity against filoviruses, including Marburg virus, Ebola virus, and Sudan virus (SUDV). We also report that once-daily oral ODV treatment of cynomolgus monkeys for 10 days beginning 24 hours after SUDV exposure confers 100% protection against lethal infection. Transcriptomics data show that ODV treatment delayed the onset of inflammation and correlated with antigen presentation and lymphocyte activation. Our results offer promise for the further development of ODV to control outbreaks of filovirus disease more rapidly.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Galveston National Laboratory, University of Texas Medical Branch, Galveston, TX, USA.
- Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
- Gilead Sciences, Inc., Foster City, CA, USA.
ORCID-Profile: Robert W Cross, Courtney Woolsey, Victor C Chu, Darius Babusis, Roy Bannister, Meghan S Vermillion, Kimberly T Barrett, Elaine Bunyan, Anh-Quan Nguyen, Danielle P Porter, Abhishek N Prasad, Daniel J Deer, Krystle N Agans, Jasmine Martinez, Mack B Harrison, Natalie S Dobias, Karla A Fenton, John P Bilello, Thomas W Geisbert
Förderung
- NIAID NIH HHS
Zitieren
APA
Cross, R. W., Woolsey, C., Chu, V. C., Babusis, D., Bannister, R., Vermillion, M. S., Geleziunas, R., Barrett, K. T., Bunyan, E., Nguyen, A. Q., Cihlar, T., Porter, D. P., Prasad, A. N., Deer, D. J., Borisevich, V., Agans, K. N., Martinez, J., Harrison, M. B., Dobias, N. S., …, & Geisbert, T. W. (2024). Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science. https://doi.org/10.1126/science.adk6176
Vancouver
Cross RW, Woolsey C, Chu VC, Babusis D, Bannister R, Vermillion MS, et al. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus. Science. 2024. doi:10.1126/science.adk6176
BibTeX
@article{Cross2024,
author = {Cross, Robert W and Woolsey, Courtney and Chu, Victor C and Babusis, Darius and Bannister, Roy and Vermillion, Meghan S and Geleziunas, Romas and Barrett, Kimberly T and Bunyan, Elaine and Nguyen, Anh-Quan and Cihlar, Tomas and Porter, Danielle P and Prasad, Abhishek N and Deer, Daniel J and Borisevich, Viktoriya and Agans, Krystle N and Martinez, Jasmine and Harrison, Mack B and Dobias, Natalie S and Fenton, Karla A and Bilello, John P and Geisbert, Thomas W},
title = {Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus},
journal = {Science},
year = {2024},
doi = {10.1126/science.adk6176}
}
EUVIMED